These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24839091)

  • 1. Serotonin-norepinephrine reuptake inhibitor desvenlafaxine for the treatment of interferon alfa-associated depression in patients with hepatitis C.
    Fábregas B; Moura A; Ávila R; Carmo R; Teixeira AL
    Braz J Psychiatry; 2014; 36(2):183. PubMed ID: 24839091
    [No Abstract]   [Full Text] [Related]  

  • 2. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.
    Kraus MR; Schäfer A; Faller H; Csef H; Scheurlen M
    Aliment Pharmacol Ther; 2002 Jun; 16(6):1091-9. PubMed ID: 12030950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sertraline treatment of interferon-alfa-induced depressive disorder.
    Schramm TM; Lawford BR; Macdonald GA; Cooksley WG
    Med J Aust; 2000 Oct; 173(7):359-61. PubMed ID: 11062791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis.
    Sarkar S; Schaefer M
    Psychosomatics; 2014; 55(3):221-34. PubMed ID: 24012293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paroxetine for the prevention of depression induced by interferon alfa.
    Kraus MR; Schäfer A; Scheurlen M
    N Engl J Med; 2001 Aug; 345(5):375-6. PubMed ID: 11484704
    [No Abstract]   [Full Text] [Related]  

  • 6. Does antidepressant medication in patients with hepatitis C undergoing interferon alpha treatment reduce therapeutic efficacy?
    Robaeys G; Wichers MC; De Bie J; Koek GH; Buntinx F; Van Os J
    Gut; 2009 Jan; 58(1):145; author reply 145-6. PubMed ID: 19091833
    [No Abstract]   [Full Text] [Related]  

  • 7. Norepinephrine-enhancing antidepressant exposure associated with reduced antiviral effect of interferon alpha on hepatitis C.
    Fialho R; Burridge A; Pereira M; Keller M; File A; Tibble J; Whale R
    Psychopharmacology (Berl); 2016 May; 233(9):1689-94. PubMed ID: 25971875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan P; Kane CP; Cohen LS
    Menopause; 2010 Jul; 17(4):700-11. PubMed ID: 20539246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression.
    Kraus MR; Schäfer A; Al-Taie O; Scheurlen M
    J Viral Hepat; 2005 Jan; 12(1):96-100. PubMed ID: 15655055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression.
    Schäfer A; Scheurlen M; Seufert J; Keicher C; Weissbrich B; Rieger P; Kraus MR
    J Hepatol; 2010 Jan; 52(1):10-5. PubMed ID: 19897271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depression and hepatitis C.
    Sangwaiya A; Chan J; Ash S
    Br J Hosp Med (Lond); 2007 Dec; 68(12):682. PubMed ID: 18186414
    [No Abstract]   [Full Text] [Related]  

  • 12. Psychiatric clearance for patients started on interferon-alpha-based therapies.
    Lotrich FE
    Am J Psychiatry; 2013 Jun; 170(6):592-7. PubMed ID: 23732965
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.
    Kraus MR; Schäfer A; Schöttker K; Keicher C; Weissbrich B; Hofbauer I; Scheurlen M
    Gut; 2008 Apr; 57(4):531-6. PubMed ID: 18079286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venlafaxine for treatment of interferon alfa-induced depression.
    Malek-Ahmadi P; Prabhu F
    Ann Pharmacother; 2006 Nov; 40(11):2075. PubMed ID: 17047142
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of interferon-alpha-associated depression with antidepressant medications in patients with hepatitis C virus: a systematic review and meta-analysis.
    Ehret M; Sobieraj DM
    Int J Clin Pract; 2014 Feb; 68(2):255-61. PubMed ID: 24372654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.
    Pae CU; Park MH; Marks DM; Han C; Patkar AA; Masand PS
    Curr Opin Investig Drugs; 2009 Jan; 10(1):75-90. PubMed ID: 19127490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing the neuropsychiatric complications of hepatitis C treatment.
    Sockalingam S; Shammi C; Stergiopoulos V
    Br J Hosp Med (Lond); 2007 Oct; 68(10):520-5. PubMed ID: 17974293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients.
    Weinrieb RM; Auriacombe M; Lynch KG; Chang KM; Lewis JD
    J Clin Psychiatry; 2003 Dec; 64(12):1502-10. PubMed ID: 14728113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desvenlafaxine: a therapeutic option for treatment of menopausal hot flashes.
    Archer DF
    Maturitas; 2010 May; 66(1):1-2. PubMed ID: 20211532
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.
    Schaefer M; Mauss S
    Curr Drug Abuse Rev; 2008 Jun; 1(2):177-87. PubMed ID: 19630716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.